Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bram Verstockt

Showing results (51-60 of 167) with videos related to

Pageof 17
Sort By:
United European Gastroenterology Journal|December 19, 2024
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank AnalysisAn Outtier, Rosanne Janssens, Liese Barbier, et al.
Clinical Pharmacokinetics|April 8, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's DiseaseWei Zhang, Zhigang Wang, Thierry Dervieux, et al.
Endoscopy International Open|January 15, 2024
Long-term follow-up of the red density pilot trial: a basis for long-term prediction of sustained clinical remission in ulcerative colitis?Pieter Sinonquel, Peter Bossuyt, João Pedro Guedelha Sabino, et al.
Inflammatory Bowel Diseases|February 24, 2021
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel DiseaseSare Verstockt, Bram Verstockt, Kathleen Machiels, et al.
Nature Reviews. Gastroenterology & Hepatology|April 17, 2023
IL-12 and IL-23 pathway inhibition in inflammatory bowel diseaseBram Verstockt, Azucena Salas, Bruce E Sands, et al.
Digestive Diseases (Basel, Switzerland)|February 27, 2025
No Increased Risk of Venous Thromboembolism or Infectious Complications after Janus Kinase Inhibitor Exposure in Patients with Ulcerative Colitis Undergoing SurgeryIne De Greef, Gabriele Bislenghi, Isabelle Terrasson, et al.
Inflammatory Bowel Diseases|August 6, 2024
Eosinophil Depletion as a Potential Therapeutic Strategy in Acute and Chronic Intestinal Inflammation Based on a Dextran Sulfate Sodium Colitis ModelInge Jacobs, Sara Deleu, Jonathan Cremer, et al.
Inflammatory Bowel Diseases|September 7, 2025
Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease PathogenesisBalazs Bohar, John P Thomas, Yufan Liu, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testingBram Verstockt, Gitte Moors, Sumin Bian, et al.
The American Journal of Gastroenterology|July 30, 2025
Inflammatory Bowel Disease and Risk of More than 1,500 Comorbidities: A Disease-wide Prediagnostic and Postdiagnostic Phenomic Association StudyAnthony C Ebert, Bram Verstockt, Martin Bøgsted, et al.
Pageof 17

Showing results (51-60 of 167) with videos related to

Sort By:
Pageof 17
United European Gastroenterology Journal|December 19, 2024
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank AnalysisAn Outtier, Rosanne Janssens, Liese Barbier, et al.
Clinical Pharmacokinetics|April 8, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's DiseaseWei Zhang, Zhigang Wang, Thierry Dervieux, et al.
Endoscopy International Open|January 15, 2024
Long-term follow-up of the red density pilot trial: a basis for long-term prediction of sustained clinical remission in ulcerative colitis?Pieter Sinonquel, Peter Bossuyt, João Pedro Guedelha Sabino, et al.
Inflammatory Bowel Diseases|February 24, 2021
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel DiseaseSare Verstockt, Bram Verstockt, Kathleen Machiels, et al.
Nature Reviews. Gastroenterology & Hepatology|April 17, 2023
IL-12 and IL-23 pathway inhibition in inflammatory bowel diseaseBram Verstockt, Azucena Salas, Bruce E Sands, et al.
Digestive Diseases (Basel, Switzerland)|February 27, 2025
No Increased Risk of Venous Thromboembolism or Infectious Complications after Janus Kinase Inhibitor Exposure in Patients with Ulcerative Colitis Undergoing SurgeryIne De Greef, Gabriele Bislenghi, Isabelle Terrasson, et al.
Inflammatory Bowel Diseases|August 6, 2024
Eosinophil Depletion as a Potential Therapeutic Strategy in Acute and Chronic Intestinal Inflammation Based on a Dextran Sulfate Sodium Colitis ModelInge Jacobs, Sara Deleu, Jonathan Cremer, et al.
Inflammatory Bowel Diseases|September 7, 2025
Patient-Specific Regulatory Network Rewiring in Inflammatory Bowel Disease: How Genetic Polymorphisms Divert Incoming Signals and Contribute to Disease PathogenesisBalazs Bohar, John P Thomas, Yufan Liu, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testingBram Verstockt, Gitte Moors, Sumin Bian, et al.
The American Journal of Gastroenterology|July 30, 2025
Inflammatory Bowel Disease and Risk of More than 1,500 Comorbidities: A Disease-wide Prediagnostic and Postdiagnostic Phenomic Association StudyAnthony C Ebert, Bram Verstockt, Martin Bøgsted, et al.
Pageof 17